K. Reich, “Efficacy and safety of ixekizumab versus adalimumab in patients with active psoriatic arthritis and moderate-to-severe psoriasis: 52-week results from the randomised SPIRIT-H2H trial”, Dermatol Pract Concept, vol. 12, no. 2, p. e2022104, May 2022, doi: 10.5826/dpc.1202a104.